Drug
Cetuximab
Cetuximab: highest development phase Phase 3, developed by Eli Lilly, Merck, Merck KGaA. 5 trial records tracked on RxWires.
- Highest phase
- Phase 3
- Developer
- Eli Lilly, Merck, Merck KGaA
Trials
| Drug | Phase | Indication |
|---|---|---|
| Cetuximab NCT02383966 | Phase 3 | Carcinoma, Squamous Cell of Head and Neck |
| cetuximab, cisplatin NCT00463788 | Phase 2 | Breast Neoplasm |
| Cetuximab NCT00865098 | Phase 2 | Carcinoma of the Head and Neck |
| Cetuximab NCT00055419 | Phase 2 | Colorectal Neoplasms |
| Cetuximab NCT00311857 | Phase 1/2 | Glioblastoma Multiforme |
Latest
No recent events.
Follow Cetuximab on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.